Merck's Leadership Position In Immuno Oncology Is Improving
January 12, 2017 at 09:06 AM EST
Merck & Co., Inc. (NYSE: MRK) unexpectedly announced a priority review for Keytruda plus chemo in first-line lung cancer. This, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.